Acta neuropathologica 2018-11
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
ABSTRACT
Related Questions
Do molecular factors (1p/19q, IDH status) influence your choice of dose/volumes?
New answer by Radiation Oncologist at University of Missouri at Columbia, Ellis Fischel Cancer Cener (April 5, 2019)
As stated above 9802 RT+PCV demonstrated survival advantage over RT alone which took years to see the OS benefit, implying a durable benefit to upfront treatment. So any high ...
When would you offer hypofractionated radiotherapy?
New comment by Radiation Oncologist at Renown Health Institute for Cancer ( October 29, 2020)
How do you get TERT promoter, EGFR amp, +7/-10 information? Are there any commercially available labs (illumina/foundation) or are these done in-house at certain universities?